[{"orgOrder":0,"company":"Ferozsons Laboratories","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Lenacapavir","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Ferozsons Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Ferozsons Laboratories \/ Ferozsons Laboratories","highestDevelopmentStatusID":"14","companyTruncated":"Ferozsons Laboratories \/ Ferozsons Laboratories"}]

Find Clinical Drug Pipeline Developments & Deals by Ferozsons Laboratories

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.

                          Brand Name : Sunlenca

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 02, 2024

                          Lead Product(s) : Lenacapavir

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : Gilead Sciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank